Zsolt T. Nagy

Budapest, BU, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Journal: American journal of hematology

Published: February 29, 2024

Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.

Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.

Journal: European journal of haematology

Published: January 16, 2023

The role of liver-specific contrast-enhanced MRI before resection of colorectal liver metastases

The role of liver-specific contrast-enhanced MRI before resection of colorectal liver metastases

Journal: Orvosi hetilap

Published: May 21, 2021

Modular Reorganization of Signaling Networks during the Development of Colon Adenoma and Carcinoma.

Modular Reorganization of Signaling Networks during the Development of Colon Adenoma and Carcinoma.

Journal: The journal of physical chemistry. B

Published: February 10, 2021

Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption.

Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption.

Journal: Mediterranean journal of hematology and infectious diseases

Published: November 17, 2020

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: September 19, 2019

Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Journal: Magyar onkologia

Published: January 17, 2017

How can we treat Waldenström's macroglobulinemia?

How can we treat Waldenström's macroglobulinemia?

Journal: Magyar onkologia

Published: January 11, 2017

Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency.

Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency.

Journal: Orphanet journal of rare diseases

Published: September 27, 2016

PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.

PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: May 24, 2016

Treatment options and limitations in the management of myelofibrosis

Treatment options and limitations in the management of myelofibrosis

Journal: Magyar onkologia

Published: April 08, 2016

Novelties in the diagnostics and therapy of hairy cell leukemia

Novelties in the diagnostics and therapy of hairy cell leukemia

Journal: Magyar onkologia

Published: March 21, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026